Page 5 - Stroke Statistics News Today

In this feature, we acknowledge the impact of the 1964 Surgeon General report, its subsequent effect on public health, and present-day hurdles to optimized public health efforts through the eyes of our editorial advisory board members and other leading experts.

High blood pressure, obesity and other risk factors continue to contribute to high rates of heart disease and stroke worldwide, including in the U.S. where annual deaths from cardiovascular disease are approaching 1 million. That's according to an exhaustive statistics report released&#x20...

Only 10% of people who experience a cardiac arrest survive.[1] In new challenge goals outlined in the American Heart Association Emergency Cardiovascular Care 2

AHA aims to double cardiac arrest survival to 20% by 2030 through increased bystander CPR and defibrillation.

The American Heart Association's report on heart disease and stroke statistics emphasizes health equity and addresses structural racism in healthcare, revealing disparities in cardiovascular risk factors and disease prevalence among different communities.

A new poll from the American Heart Association reports that half of people in the United States don't know that heart disease is the nation's leading cause of death. Experts say there are health dangers associated with that lack of knowledge.

More than half of people in the U.S. (51%) do not know that heart disease is the leading cause of death in the country, according to a recent Harris Poll survey conducted on behalf of the American Heart Association in November 2023.

Heart disease remains the leading cause of death in U.S., according to a new report from the American Heart Association; yet fewer than half of survey....

The American Heart Association's annual report on heart disease and stroke statistics for 2024 sheds new light on the impact and level of public education surrounding the impact of heart disease and stroke in the US and abroad.

Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be more than 750,000 patients annually worldwide